Shots:
- AbbVie has reported topline P-II (ELATE) trial data assessing Botox (onabotulinumtoxinA) vs PBO in pts with upper limb essential tremor
- Trial met its 1EP with improved Tremor Disability Scale-Revised scores at 18wks. & showed a greater TREDS-R total unilateral score reduction (-2.61 vs -1.61), plus it also achieved all six 2EPs; data to be presented at International Congress of Parkinson’s Disease and Movement Disorders 2025
- Botox received its first FDA approval for blepharospasm & strabismus in adults & is now approved for multiple conditions, incl. chronic migraine, overactive bladder, spasticity, cervical dystonia, sev. underarm sweating, & urine incontinence due to detrusor overactivity associated with a neurologic condition in pts (≥5yrs.)
Ref: AbbVie | Image: AbbVie | Press Release
Related News:- AbbVie Reports the US FDA’s BLA Submission of Pivekimab Sunirine to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
